Treatment Options for Progressive Stage IV, Relapsed, and Recurrent NSCLC (Second-Line Therapy)

Chemotherapy.

Chemotherapy.

Docetaxel.

Chemotherapy.

Docetaxel plus ramucirumab.

Chemotherapy.

Datopotamab deruxtecan.

Chemotherapy.

Pemetrexed.

EGFR-directed therapy.

EGFR-directed therapy.

EGFR-directed therapy after first-line chemotherapy (for patients with EGFR-sensitizing variants).

EGFR-directed therapy. › EGFR-directed therapy after first-line chemotherapy (for patients with EGFR-sensitizing variants).

Erlotinib.

EGFR-directed therapy. › EGFR-directed therapy after first-line chemotherapy (for patients with EGFR-sensitizing variants).

Gefitinib.

EGFR-directed therapy. › EGFR-directed therapy after first-line chemotherapy (for patients with EGFR-sensitizing variants).

Afatinib.

EGFR-directed therapy.

EGFR-directed therapy (for patients with acquired EGFR T790M variants after previous EGFR-directed therapy).

EGFR-directed therapy. › EGFR-directed therapy (for patients with acquired EGFR T790M variants after previous EGFR-directed therapy).

Osimertinib.

EGFR-directed therapy.

EGFR-directed therapy after first-line chemotherapy (for patients with EGFR exon 20 insertions).

EGFR-directed therapy. › EGFR-directed therapy after first-line chemotherapy (for patients with EGFR exon 20 insertions).

Amivantamab.

EGFR-directed therapy. › EGFR-directed therapy after first-line chemotherapy (for patients with EGFR exon 20 insertions).

Amivantamab plus chemotherapy.

EGFR-directed therapy. › EGFR-directed therapy after first-line chemotherapy (for patients with EGFR exon 20 insertions).

Subcutaneous amivantamab-lazertinib.

ALK-directed tyrosine kinase inhibitors (TKIs).

ALK-directed tyrosine kinase inhibitors (TKIs).

ALK-directed TKIs after first-line chemotherapy.

ALK-directed tyrosine kinase inhibitors (TKIs). › ALK-directed TKIs after first-line chemotherapy.

Crizotinib.

ALK-directed tyrosine kinase inhibitors (TKIs).

ALK-directed TKIs after prior ALK TKI therapy.

ALK-directed tyrosine kinase inhibitors (TKIs). › ALK-directed TKIs after prior ALK TKI therapy.

Ceritinib.

ALK-directed tyrosine kinase inhibitors (TKIs). › ALK-directed TKIs after prior ALK TKI therapy.

Alectinib.

ALK-directed tyrosine kinase inhibitors (TKIs). › ALK-directed TKIs after prior ALK TKI therapy.

Brigatinib.

ALK-directed tyrosine kinase inhibitors (TKIs). › ALK-directed TKIs after prior ALK TKI therapy.

Lorlatinib.

BRAF V600E and MEK inhibitors (for patients with BRAF V600E variants).

BRAF V600E and MEK inhibitors (for patients with BRAF V600E variants).

Dabrafenib and trametinib.

ROS1-directed therapy.

ROS1-directed therapy.

Entrectinib.

ROS1-directed therapy.

Crizotinib.

ROS1-directed therapy.

Repotrectinib (for both ROS1 TKI-naïve and ROS1 TKI-treated patients).

NTRK inhibitors (for patients with NTRK fusions).

NTRK inhibitors (for patients with NTRK fusions).

Larotrectinib.

NTRK inhibitors (for patients with NTRK fusions).

Entrectinib.

RET inhibitors (for patients with RET fusions).

RET inhibitors (for patients with RET fusions).

Selpercatinib.

RET inhibitors (for patients with RET fusions).

Pralsetinib.

MET inhibitors (for patients with MET exon 14-skipping variants).

MET inhibitors (for patients with MET exon 14-skipping variants).

Tepotinib.

MET inhibitors (for patients with MET exon 14-skipping variants).

Capmatinib.

KRAS G12C inhibitors (for patients with KRAS G12C variants).

KRAS G12C inhibitors (for patients with KRAS G12C variants).

Adagrasib.

KRAS G12C inhibitors (for patients with KRAS G12C variants).

Sotorasib.

HER2-targeted therapy (for patients with HER2 variants).

HER2-targeted therapy (for patients with HER2 variants).

Trastuzumab deruxtecan.

Immunotherapy.

Immunotherapy.

Nivolumab.

Immunotherapy.

Pembrolizumab.

Immunotherapy.

Atezolizumab.

mTOR inhibitors (for patients with unresectable, locally advanced or metastatic, progressive, well-differentiated, nonfunctional, neuroendocrine tumors).

mTOR inhibitors (for patients with unresectable, locally advanced or metastatic, progressive, well-differentiated, nonfunctional, neuroendocrine tumors).

Everolimus.

Clinical trials can be considered as second-line therapy.